Sepsis. Other sepsis
Conditions
Interventions
Intervention 1: Intervention group: 3000 mg of L-carnitine in 3 doses (1000 mg) 3 times a day for 7 days. From KAREN Trading Company. Intervention 2: Control group: 3000 mg Maltodextrin in 3 doses (10
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Diagnosis of sepsis based on blood culture and approval of an ICU specialist and anesthesiologist and infectious disease specialist Gastrointestinal with normal function and intestinal nutrition criteria Accept informed consent Age>=18
Exclusion criteria
Exclusion criteria: Patient or family dissatisfaction Patients who are hospitalized in the ICU for less than 48 hours or do not have the possibility of intestinal feeding and patients who receive nutritional support with full intravenous feeding Patients who do not have an indication for intestinal nutrition on the first day and are confirmed and predicted based on the diagnosis of the intensive care unit that they will not be able to receive intestinal nutrition in the future. (Nausea, persistent vomiting, ileus, intestinal obstruction, uncontrolled diarrhea (> 500 ml per day), high-output fistula (> 500 ml per day), intestinal inaccessibility, incomplete resuscitation and hemodynamic instability Cancer patients undergoing chemotherapy and taking cisplatin Patients taking anticonvulsants (phenobarbital and phenytoin) Patients taking pivalic acid, valproic acid and Ifosfamide Patients taking levetiracetam Patients undergoing dialysis Patients with hyperthyroidism and hypothyroidism Pregnancy Severe and progressive septic shock Patients who are expected to die within 2 days of admission to the ICU Patients with BMI<18.5 kg/m2 admitted to the ICU
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| C reactive Protein (CRP). Timepoint: At baseline and end of the study. Method of measurement: ELISA test.;Erythrocyte sedimentation rate (ESR). Timepoint: At baseline and end of the study. Method of measurement: ELISA test.;Total antioxidant capacity (TAC). Timepoint: At baseline and end f the study. Method of measurement: Commercial diagnostic kit.;Superoxide dismutase (SOD). Timepoint: At baseline and end f the study. Method of measurement: Commercial diagnostic kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| 28 mortality rate. Timepoint: End of the study. Method of measurement: Mathematically dividing the number of dead people by the total number of people using hospital records or telephone follow-up.;Complete blood count (CBC). Timepoint: End of the study. Method of measurement: ELISA kits. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Bagherniya
Esfahan University of Medical Sciences
Outcome results
None listed